About Us
Contact Us
Subscriber Services
e-Edition
Obituaries

Penticton Herald

Home
News
Sports
Business News
Entertainment
Life
Opinion
- Columnists
- Letters to Editor
Classifieds
- Place Ad
- Obituaries
Contests
OK Bids

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

34.70 +3.58 (+11.50%)

Streaming Delayed Price Updated: 1:27 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

Top stock movements in today's session. ↗

January 12, 2026

Via Chartmill

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Is Beam Therapeutics Gaining or Losing Market Support? ↗

September 22, 2025

Via Benzinga

What Does the Market Think About Beam Therapeutics? ↗

August 25, 2025

Via Benzinga

Beam Therapeutics (BEAM) Earnings Transcript ↗

November 27, 2025

Beam Therapeutics (BEAM) Earnings Transcript

Via The Motley Fool

Topics Death

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...

Via Benzinga

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

October 09, 2025

New York, NY – October 9, 2025 – In a significant move set to ripple through the biotech sector, Jefferies has initiated coverage of Beam Therapeutics (NASDAQ: BEAM) with a coveted "Buy" rating. This...

Via MarketMinute

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗

October 08, 2025

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therapeutics (BEAM) and Shopify (SHOP).

Via Benzinga

Topics Artificial Intelligence

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Via MarketMinute

Topics Artificial Intelligence Climate Change Economy

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗

August 15, 2025

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Via Benzinga

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies ↗

June 27, 2025

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab ↗

June 11, 2025

Via Benzinga

10 Analysts Assess Beam Therapeutics: What You Need To Know ↗

May 07, 2025

Via Benzinga

Why Beam Therapeutics Stock Tanked on Tuesday ↗

May 06, 2025

Via The Motley Fool

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease ↗

April 07, 2025

Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗

April 04, 2025

Via Benzinga

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' ↗

April 04, 2025

Via Benzinga

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

March 28, 2025

Via Benzinga

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock ↗

March 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Contact us

pentictonherald.ca

Penticton Herald
Phone number: 250-492-4002
E-mail: csr@ok.bc.ca
Address: 186 Nanaimo Ave. W.
Penticton, BC V2A 1N4

Sections

Home
Sports
Business News
Entertainment
Life
Opinion
Photos
Videos
Obituaries

Services

About Us
Contact Us
Personnel
Careers
Subscription Services
Submission Forms
Site Index
Add Search Toolbar
Privacy Policy & Terms
e-tearsheets

Search

Search in:

All
News
Sports

Entertainment
Business News
Life

Opinion
Photos
Video